Omeprazol Basi (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Basi, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults and children.

GNH USA supplies Omeprazol Basi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazol Basi is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for: - Gastro‑oesophageal reflux disease (GERD): relief of heartburn and erosion healing. - Peptic ulcer disease: promotes ulcer healing and reduces recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild and transient. - Diarrhea: usually self‑limiting. - Nausea: occasional mild upset. - Abdominal pain: mild cramping. - Flatulence: excess gas. - Constipation: occasional bowel change.

Serious or Rare Side Effects: - Acute interstitial nephritis: inflammation of kidney tissue. - Clostridioides difficile infection: severe colitis. - Hypomagnesemia: low magnesium levels with prolonged use. - Stevens‑Johnson syndrome: rare severe skin reaction. - Fracture risk: possible reduction in bone density with long‑term therapy.

When prescribing Omeprazol Basi, consider the following precautions: - Assess renal function: adjust use in severe impairment. - Evaluate hepatic function: use with caution in liver disease. - Review long‑term use: monitor for bone density loss. - Pregnancy and lactation: weigh benefits against potential risks. - Drug‑interaction review: check concomitant medications. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Omeprazole may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect. - Atazanavir: decreased antiviral absorption. - Dasatinib: lowered cancer‑drug exposure.

Moderate Interactions (Monitor Closely): - Warfarin: potential INR elevation. - Phenytoin: decreased phenytoin levels. - Methotrexate: increased toxicity risk.